INTRODUCTION:

Ayahuasca is a traditional hallucinogenic beverage that has its origins deeply rooted in the traditions of indigenous civilisations in the Amazon Basin who are concerned with spirituality and healing. The usage of ayahuasca in shamanic rituals, where it is thought to enhance communication with spiritual realms, offer insight into personal and collective experiences, and promote physical and mental healing, has been going on for millennia.

Ayahuasca is revered as a sacred medicine. The use of ayahuasca has garnered attention from all over the world in recent years because to the possible therapeutic benefits it may offer, notably in the areas of mental health, emotional healing, and addiction rehabilitation. This interest has spread well beyond the indigenous peoples who brought it into existence.^1,2

In most cases, the synthesis of ayahuasca includes combining two basic plant components: the leaves of the Psychotria viridis shrub and the vine known as Banisteriopsis caapi respectively. The psychedelic qualities of ayahuasca are mostly attributed to these plants, which work in a synergistic coordination with one another. A number of beta-carbolines, including harmine, harmaline, and tetrahydroharmine, are found in Banisteriopsis caapi. These beta-carbolines are known to be monoamine oxidase inhibitors (MAOIs). There is a significant amount of the powerful hallucinogenic chemical known as N,N-dimethyltryptamine (DMT) in the leaves of the Psychotria viridis plant. Under typical conditions, MAO enzymes are responsible for the rapid breakdown of DMT in the digestive system, which renders it inert when it is taken orally. On the other hand, the beta-carbolines contained in Banisteriopsis caapi are able to inhibit these enzymes, which enables DMT to enter the brain and generate its profound psychedelic effects. An essential component of the ayahuasca experience is the pharmacological interaction described here.

The effects of ayahuasca are highly variable and depend on a number of factors, including the dose, the environment, and the individual. Experiences such as strong visual hallucinations, changed perceptions of time and space, and a heightened emotional state are frequently reported by individuals who have had this condition. Numerous people have reported experiencing a profound sense of introspection, which involves confronting inner fears, traumatic experiences, and emotional barriers. Due to the fact that the beverage is capable of eliciting such profound interior experiences, there has been a growing interest in the possible therapeutic applications of the beverage. Ayahuasca may be useful in treating diseases such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders, according to preliminary findings from scientific research. This provides a glimmer of hope for those who are looking for alternative approaches to healing and personal development. scientific research, continues to shed light on its one-of-a-kind pharmacological composition and its capacity to bring significant psychological and emotional healing. As a result, ayahuasca has become a subject of both intrigue and controversy.^3,4

Pharmacognosy of Ayahuvasca:

Ayahuasca is typically prepared using two main plants: Banisteriopsis caapi and Psychotria viridis. Each of these plants contains bioactive compounds that work together to produce the desired psychoactive effects.

Figure 1: Ayahuvasca

1. Banisteriopsis caapi (B. caapi):

This vine is the cornerstone of the Ayahuasca brew, serving as the MAO (monoamine oxidase) inhibitor. Banisteriopsis caapi contains beta-carboline alkaloids, primarily harmine, harmaline, and tetrahydroharmine. These alkaloids inhibit the enzyme monoamine oxidase in the gastrointestinal system, which is responsible for breaking down DMT (N,N-Dimethyltryptamine) when ingested orally. Without this inhibition, DMT would not reach the brain and would be rapidly metabolized in the body. The inhibition of MAO allows DMT to become orally active, triggering Ayahuasca’s profound psychoactive effects. Beyond MAO inhibition, these beta-carbolines are also believed to have neuroprotective properties, possibly aiding in neurogenesis and the promotion of neural plasticity, which may contribute to Ayahuasca’s therapeutic effects on mental health.

2. Psychotria viridis (P. viridis):

Figure 2: P.Viridis plant

The leaves of Psychotria viridis contain DMT, the primary hallucinogenic compound in Ayahuasca. DMT is a tryptamine molecule that is structurally similar to the neurotransmitter serotonin. When ingested and allowed to cross the blood-brain barrier (thanks to the MAO-inhibiting action of B. caapi), DMT binds to serotonin receptors, particularly the 5-HT2A receptor, leading to intense visual and sensory experiences. DMT is responsible for the characteristic hallucinations, altered perceptions of reality, and deep introspective journeys commonly associated with Ayahuasca consumption.^5,6

Chemical Interactions:

The pharmacognostic interaction between B. caapi and P. viridis is a key aspect of Ayahuasca’s effects. The combination of MAO inhibitors from Banisteriopsis caapi with the DMT in Psychotria viridis enables the psychoactive properties to manifest. Additionally, this interaction allows for prolonged periods of heightened sensory and emotional awareness, often accompanied by visions, introspection, and a sense of interconnectedness.

Other Constituents and Regional Variations:

In some traditional preparations of Ayahuasca, other plants are occasionally added to modify or enhance the brew’s effects. Examples include Diplopterys cabrerana, which contains higher concentrations of DMT, or other herbs for specific spiritual purposes. These regional variations showcase the ethnopharmacological depth of Ayahuasca, reflecting diverse traditional knowledge and applications across different Amazonian cultures.^7,8

Therapeutic Potential:

From a pharmacognostic perspective, the synergy between DMT and MAO inhibitors in Ayahuasca offers unique therapeutic possibilities. The brew has been studied for its potential to treat mental health disorders, including depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders. The beta-carbolines in B. caapi may promote neuroplasticity, helping individuals reframe negative thought patterns, while the DMT component induces altered states of consciousness that facilitate deep emotional healing.

Why Ayahuasca is Banned in Many Countries:

Ayahuasca, despite its historical significance and growing interest for its potential therapeutic benefits, is banned or restricted in many countries around the world. The primary reasons for its legal prohibition stem from its psychoactive properties, health concerns, and regulatory frameworks governing controlled substances.

1. Presence of a Controlled Substance (DMT):

The main reason Ayahuasca is illegal in many countries is its DMT (N,N-Dimethyltryptamine) content. DMT is a powerful hallucinogen that is classified as a Schedule I drug under the United Nations Convention on Psychotropic Substances (1971). Schedule I substances are those deemed to have a high potential for abuse, no accepted medical use, and a lack of safety under medical supervision. Many countries, including the United States, Canada, the UK, and various European nations, have adopted these conventions into their national drug laws, making the possession, use, or distribution of DMT illegal.

Ayahuasca’s psychoactive effects arise primarily from the DMT found in Psychotria viridis (one of the plants in the brew). Since DMT is classified as an illegal drug in most jurisdictions, Ayahuasca itself is often treated as a controlled substance.^9,10,11

2. Potential for Abuse and Misuse:

Although Ayahuasca is traditionally used in a controlled, ritualistic context by indigenous groups, concerns about its misuse in non-traditional settings have contributed to its prohibition. Outside of shamanic ceremonies, there is a risk that people may consume Ayahuasca recreationally, without the proper guidance, understanding, or respect for its powerful psychoactive effects. The experience can be highly intense, leading to both positive and negative psychological effects, including distress, paranoia, or severe emotional reactions.

3. Lack of Standardized Regulation and Medical Supervision:

Another reason for Ayahuasca’s prohibition is the absence of standardized regulation and medical oversight. While Ayahuasca has been studied for its therapeutic potential in treating conditions like depression, anxiety, PTSD, and addiction, it has not yet been approved by major medical regulatory bodies like the FDA (Food and Drug Administration) or EMA (European Medicines Agency). The unpredictable nature of the brew’s effects, combined with the lack of medical supervision in many settings where it is consumed, raises concerns about its safety.

4. Cultural and Ethical Concerns:

Some countries also ban Ayahuasca due to concerns about cultural appropriation and unethical practices surrounding its use in non-traditional contexts. With the rise of Ayahuasca tourism, especially in South America, there have been reports of exploitation and commercialization of indigenous traditions. These concerns include the commodification of spiritual practices, lack of respect for the cultural heritage of Amazonian tribes, and instances where untrained or fraudulent "shamans" lead ceremonies, resulting in unsafe conditions for participants.

5. Health Risks and Legal Liability:

Ayahuasca is known for causing intense physical reactions, such as vomiting, diarrhea, and in rare cases, heart-related complications. While these physical responses are often considered a part of the purging and healing process in traditional ceremonies, they raise health concerns in countries where the brew is used without adequate medical supervision. There have been instances of fatal outcomes, particularly when individuals with pre-existing health conditions, such as heart disease or mental health issues, consume Ayahuasca. The legalization of Ayahuasca is a complex and controversial issue, but it is possible under certain conditions. Whether Ayahuasca could be legalized depends on several factors, including its cultural, medical, and legal implications. While there are cases where it has been decriminalized or legalized under specific circumstances, full legalization would require addressing concerns around safety, regulation, and cultural appropriation.^12,13,14

1. Medical and Scientific Research:

One potential pathway to Ayahuasca’s legalization is through increased scientific research and clinical trials. There is growing interest in Ayahuasca’s potential therapeutic benefits, particularly in treating conditions like depression, anxiety, post-traumatic stress disorder (PTSD), and addiction. Emerging research has shown that the brew may have profound healing effects on mental health, as it promotes neuroplasticity and emotional processing. However, large-scale, controlled clinical studies are still limited.

2. Religious and Spiritual Use:

In certain countries, Ayahuasca is legal or decriminalized when used in religious contexts. In Brazil, for example, Ayahuasca is legal for use in specific ceremonial settings by members of recognized religious groups, such as the Santo Daime and União do Vegetal (UDV) churches. These organizations have argued that Ayahuasca is a sacrament essential to their spiritual practices, and their right to use it is protected by religious freedom laws.Legalization for religious or spiritual purposes could be a viable model, provided that the use is regulated and confined to specific settings, under the guidance of trained facilitators who respect the cultural and traditional origins of Ayahuasca.

3. Harm Reduction and Regulation:

Some advocates argue for the legalization of Ayahuasca under a harm-reduction model. This approach recognizes that people are already using Ayahuasca in many countries, often in unregulated or underground settings, which can lead to unsafe conditions. By legalizing Ayahuasca, governments could establish regulations to ensure its safe use, much like alcohol or cannabis.

4. Cultural and Ethical Considerations:

One of the challenges of Ayahuasca legalization is the issue of cultural appropriation and ethical concerns surrounding its use in non-traditional contexts. Ayahuasca has deep cultural significance for the indigenous peoples of the Amazon, who have used the brew for centuries in their spiritual and healing practices. Some indigenous groups are concerned about the commercialization and exploitation of Ayahuasca by outsiders, especially in the context of Ayahuasca tourism.

5. Challenges to Legalization:

Public health concerns: Governments are wary of the potential risks associated with Ayahuasca, including its intense psychoactive effects, the possibility of psychological distress, and rare but serious physical reactions.

International drug control treaties: As DMT is classified as a Schedule I drug under international drug control treaties, any move to legalize Ayahuasca could face challenges on a global scale. Potential for abuse: While Ayahuasca is traditionally used in ceremonial or therapeutic settings, there are concerns that legalization could lead to recreational misuse or commercialization, similar to what has happened with other psychedelics.^15,16,17

CONCLUSION:

Despite its promising therapeutic potential, Ayahuasca remains banned in many countries, primarily due to the presence of DMT, a Schedule I substance under international drug control laws. Concerns over its misuse, lack of standardized regulation, and the potential for serious health risks have led to widespread legal restrictions. Furthermore, cultural and ethical concerns regarding its use outside traditional contexts, such as the commercialization of Ayahuasca tourism, have contributed to its controversial status.

The possibility of Ayahuasca’s legalization hinges on several factors, including increased scientific research, its potential medical use, and its recognition for religious and spiritual purposes. A harm-reduction model could also pave the way for safe, regulated use. However, challenges remain, including addressing public health concerns, navigating international drug treaties, and ensuring that indigenous rights and cultural practices are respected

REFERENCES:

1. Adayev T, Murata T, Wang R, Hegde AN, Song WJ. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Arch Biochem Biophys. 2011; 507(2): 212-218.

2. Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sampedro F. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol. 2015; 25(4): 483-492.

3. Buchsbaum MS, DeLuca H, Haier RJ, Hazlett E, Syrjala K, Wu J, et al. Simultaneous cerebral glucography with positron emission tomography and topographic electroencephalography. Prog Brain Res. 1984; 62: 343-349.

4. Buckholtz NS, Boggan WO, Freedman DX. Monoamine-oxidase inhibition in brain and liver produced by beta-carbolines—structure-activity-relationships and substrate-specificity. Biochem Pharmacol. 1977; 26(19): 1991-1996.

5. de Munck JC, Gonçalves SI, Faes TJ, Heethaar RM, Lopes da Silva FH. The hemodynamic response of the alpha rhythm: an EEG/fMRI study. Neuroimage. 2007; 35(3): 1142-1151.

6. de Munck JC, Gonçalves SI, Mammoliti R, Heethaar RM, Lopes da Silva FH. Interactions between different EEG frequency bands and their effect on alpha-fMRI correlations. Neuroimage. 2009; 47(1): 69-76.

7. DeSteno DA, Schmauss C, Kruger JM. Induction of early growth response gene 2 expression in the forebrain of mice performing an attention-set-shifting task. Neuroscience. 2008; 152(4): 931-939.

8. Dunmore E, Clark DM, Ehlers A. Cognitive factors involved in the onset and maintenance of posttraumatic stress disorder (PTSD) after physical or sexual assault. Behav Res Ther. 1999; 37(9): 809-829.

9. Dutta A, McKie S, Deakin JFW. Resting state networks in major depression. Psychiatry Res. 2014; 224(3): 139-151.

10. Fabregas JM, Gonzalez D, Fondevila S, Cutchet M, Fernandez X, Barbosa PC, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend. 2010; 111(3): 257-261.

11. Farzin D, Mansouri N, Faghih-Monzavi Z. Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test. Eur Neuropsychopharmacol. 2006; 16(5): 324-328.

12. Fortunato JJ, Réus GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F, et al. Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(8): 1425-1430.

13. Fortunato JJ, Réus GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F, et al. Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res Bull. 2010; 81(4-5): 491-496.

14. Frankel P, Cunningham KA, McGough NN, Collins JM, Jentsch JD. The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-fos in rat forebrain. Brain Res. 2002; 929(2): 179-186.

15. Fresco DM, Segal ZV, Buis T, Kennedy S. Initial psychometric properties of the experiences questionnaire: validation of a self-report measure of decentering. Behav Ther. 2007; 38(3): 234-246.

16. Gewirtz JC, Simoni KS. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav. 2002; 73(4): 723-731.

17. Glennon RA, Titeler M, McKenney JD. Evidence for 5-Ht2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984; 35(25): 2505-2511.

Received on 09.10.2024 Revised on 17.02.2025

Accepted on 08.05.2025 Published on 01.10.2025

Available online from October 04, 2025

Research J. Pharmacy and Technology. 2025;18(10):5061-5065.

DOI: 10.52711/0974-360X.2025.00731

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.